PI3K/mTOR Kinase Inhibitor WXFL10030390 clinical trials
Also written WX390 and WXFL10030390.
Its developmentBy Shanghai Jiatan Pharmatech, step by step6 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses PI3K/mTOR Kinase Inhibitor WXFL10030390 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PI3K/mTOR Kinase Inhibitor WXFL10030390 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Who runs them
Industry 6 · Other 0
Shanghai Jiatan Pharmatech Co., Ltd (6)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses PI3K/mTOR Kinase Inhibitor WXFL10030390 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based TreatmentNot yet recruitingPhase 3Shanghai Jiatan Pharmatech Co., LtdNCT07392060Written as WX390 1.1mg + Toripalimab 240mg
- A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 MutationsRecruitingPhase 2Shanghai Jiatan Pharmatech Co., LtdNCT06124963Written as WX390
- A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Jiatan Pharmatech Co., LtdNCT06117566Written as WX390
- A Study of WX390 in Patients With Advanced Solid TumorsRecruitingPhase 2Shanghai Jiatan Pharmatech Co., LtdNCT06117540Written as WX390
- A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA MutationsCompletedPhase 1/2Shanghai Jiatan Pharmatech Co., LtdNCT06132932Written as WX390
- A Study of WXFL10030390 in Patients With Advanced Solid Tumors or LymphomaCompletedPhase 1Shanghai Jiatan Pharmatech Co., LtdNCT03730142Written as WXFL10030390